Rifampicin.
D000256:Adenoviridae / Q000187:drug effects; D000284:Administration, Oral; D000818:Animals; D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy; D012321:DNA-Directed RNA Polymerases; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000188:drug therapy*; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D009161:Mycobacterium / Q000187:drug effects; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy; D014615:Vaccinia / Q000188:drug therapy; D014616:Vaccinia virus / Q000187:drug effects
D012321:DNA-Directed RNA Polymerases; D007538:Isoniazid; D012293:Rifampin